- Abbvie Inc To Acquire Cerevel Therapeutics TranscriptDec 07, 2023
- Q3 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptNov 01, 2023€22.2 (+3.74%)Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Q2 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptAug 02, 2023€27.4 (-0.72%)Earnings
- Cerevel Therapeutics Holdings Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Q1 2023 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptMay 03, 2023€26.6 (-4.32%)Earnings
- Cerevel Therapeutics Holdings Inc at Stifel CNS Days (Virtual) TranscriptMar 29, 2023
- Cerevel Therapeutics Holdings Inc at Cowen Health Care Conference TranscriptMar 06, 2023
- Q4 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptFeb 22, 2023€28.8 (-7.10%)Earnings
- Cerevel Therapeutics Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Q3 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptNov 08, 2022Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptAug 01, 2022Earnings
- Q1 2022 Cerevel Therapeutics Holdings Inc Earnings Call TranscriptMay 10, 2022Earnings
- Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 13, 2021
- Cerevel Therapeutics Holdings Inc at Citi BioPharma Conference (Virtual) TranscriptSep 08, 2021
- Cerevel Therapeutics Holdings Inc R&D Event TranscriptJan 28, 2021
Cerevel Therapeutics Holdings Inc R&D Event Transcript
Good morning, and welcome to Cerevel's first R&D event. Thank you for joining us. I'm Matthew Calistri, Vice President of Investor Relations. (Operator Instructions)
Before we begin, I'll make the following disclaimer. During the presentation, we will make certain forward-looking statements that reflect our current views related to our financial performance, future events and industry and market conditions as well as forward-looking statements, including the potential attributes and benefits of Cerevel's product candidates and the format and timing of Cerevel's product development activities and clinical trials. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. We strongly encourage you to review the information that Cerevel files with the SEC regarding specific risks and uncertainties.
I'll now turn it over to Tony Coles, Chairman and CEO of Cerevel Therapeutics. Thank you.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)